These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 32170634)

  • 1. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
    Ishiguro H; Masuda N; Sato N; Higaki K; Morimoto T; Yanagita Y; Mizutani M; Ohtani S; Kaneko K; Fujisawa T; Takahashi M; Kadoya T; Matsunami N; Yamamoto Y; Ohno S; Takano T; Morita S; Tanaka-Mizuno S; Toi M
    Breast Cancer Res Treat; 2020 Apr; 180(3):715-724. PubMed ID: 32170634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
    Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
    Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2
    Kuwayama T; Nakamura S; Hayashi N; Takano T; Tsugawa K; Sato T; Kitani A; Okuyama H; Yamauchi H
    Clin Breast Cancer; 2018 Dec; 18(6):474-480. PubMed ID: 30072191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer.
    Yardley DA; Shipley D; Zubkus J; Wright GL; Ward PJ; Mani A; Shastry M; Finney L; DeBusk L; Hainsworth JD
    Clin Breast Cancer; 2019 Feb; 19(1):1-9. PubMed ID: 30245148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
    Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
    Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.
    Narui K; Ishikawa T; Shimizu D; Yamada A; Tanabe M; Sasaki T; Oba MS; Morita S; Nawata S; Kida K; Mogaki M; Doi T; Tsugawa K; Ogata H; Ota T; Kosaka Y; Sengoku N; Kuranami M; Niikura N; Saito Y; Suzuki Y; Suto A; Arioka H; Chishima T; Ichikawa Y; Endo I; Tokuda Y
    Breast; 2019 Oct; 47():1-9. PubMed ID: 31229857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
    Earl HM; Hiller L; Dunn JA; Blenkinsop C; Grybowicz L; Vallier AL; Abraham J; Thomas J; Provenzano E; Hughes-Davies L; Gounaris I; McAdam K; Chan S; Ahmad R; Hickish T; Houston S; Rea D; Bartlett J; Caldas C; Cameron DA; Hayward L;
    Lancet Oncol; 2015 Jun; 16(6):656-66. PubMed ID: 25975632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
    Schneeweiss A; Marmé F; Ruiz A; Manikhas AG; Bottini A; Wolf M; Sinn HP; Mansouri K; Kennedy L; Bauknecht T
    Ann Oncol; 2011 Mar; 22(3):609-617. PubMed ID: 20732932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
    Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
    Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
    Mavroudis D; Saloustros E; Malamos N; Kakolyris S; Boukovinas I; Papakotoulas P; Kentepozidis N; Ziras N; Georgoulias V;
    Ann Oncol; 2015 Jul; 26(7):1333-40. PubMed ID: 25935793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.
    Gonçalves A; Pierga JY; Ferrero JM; Mouret-Reynier MA; Bachelot T; Delva R; Fabbro M; Lerebours F; Lotz JP; Linassier C; Dohollou N; Eymard JC; Leduc B; Lemonnier J; Martin AL; Boher JM; Viens P; Roché H
    Ann Oncol; 2015 Aug; 26(8):1692-7. PubMed ID: 25943350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
    Masuda N; Higaki K; Takano T; Matsunami N; Morimoto T; Ohtani S; Mizutani M; Miyamoto T; Kuroi K; Ohno S; Morita S; Toi M
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):229-38. PubMed ID: 24871032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility study of docetaxel and cyclophosphamide six- cycle therapy as adjuvant chemotherapy for Japanese human epidermal growth factor receptor 2-negative breast cancer patients.
    Abe H; Mori T; Kawai Y; Tomida K; Kubota Y; Umeda T; Tani T
    Asian Pac J Cancer Prev; 2013; 14(8):4835-8. PubMed ID: 24083754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
    Nitz U; Gluz O; Clemens M; Malter W; Reimer T; Nuding B; Aktas B; Stefek A; Pollmanns A; Lorenz-Salehi F; Uleer C; Krabisch P; Kuemmel S; Liedtke C; Shak S; Wuerstlein R; Christgen M; Kates RE; Kreipe HH; Harbeck N;
    J Clin Oncol; 2019 Apr; 37(10):799-808. PubMed ID: 30785826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
    Ueno T; Masuda N; Sato N; Ohtani S; Yamamura J; Matsunami N; Kashiwaba M; Takano T; Takahashi M; Kaneko K; Ohno S; Morita S; Toi M
    Jpn J Clin Oncol; 2020 Jan; 50(1):3-11. PubMed ID: 31821506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
    Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
    J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
    Martin M; Brase JC; Calvo L; Krappmann K; Ruiz-Borrego M; Fisch K; Ruiz A; Weber KE; Munarriz B; Petry C; Rodriguez CA; Kronenwett R; Crespo C; Alba E; Carrasco E; Casas M; Caballero R; Rodriguez-Lescure A
    Breast Cancer Res; 2014 Apr; 16(2):R38. PubMed ID: 24725534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.